PCSK9 inhibitors: Going forward and beyond

Abifadel M Varret M Rabes JP , et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154–156.

Veljic I Polovina M Milinkovic I , et al. Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 inhibitors: do we have a vanquishing new strategy? Eur J Prev Cardiol 2019; 26: 739–742.

Zenti MG Altomari A Lupo MG , et al. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol 2018; 25: 1843–1851.

Zhang DW Lagace TA Garuti R , et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007; 282: 18602–18612.

Fitzgerald K Frank-Kamenetsky M Shulga-Morskaya S , et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014; 383 60–68.

Robinson JG Nedergaard BS Rogers WJ , et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014; 311: 1870–1882.

Sabatine MS Giugliano RP Wiviott SD , et al.; for the Open-label study of long-term evaluation against LDLCI. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500–1509.

Sabatine MS Giugliano RP Keech AC , et al.; for the FOURIER Steering Committee and Investigators . Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

Schwartz GG Steg PG Szarek M , et al.; for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097–2107.

Giugliano RP Keech A Murphy SA , et al. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. JAMA Cardiol 2017; 2: 1385–1391.

Giugliano RP Pedersen TR Park JG , et al.; FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 2017; 390: 1962–1971.

Sever P Gouni-Berthold I Keech A , et al. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Eur J Prev Cardiol, Epub ahead of print 4 February 2020. DOI: 10.1177/2047487320902750.

Mach F Baigent C Catapano AL , et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–188.